Business
RBI Adds Seven More Platforms To Alert List Of Unauthorised Forex Trading Platforms
 "RBI Adds Seven More Platforms To Alert List Of Unauthorised Forex Trading Platforms")
New Delhi: The Reserve Bank of India (RBI) has expanded its ‘Alert List’ of unauthorised forex trading platforms by adding seven new entities and their websites, cautioning the public against engaging with them for currency trading. The newly flagged platforms are Starnet FX (www.starnetfx.com), CapPlace (www.capplace.com), Mirrox (www.mirrox.com), Fusion Markets (www.fusionmarkets.com), Trive (www.trive.com), NXG Markets (www.nxgmarkets.com) and Nord FX (www.nordfx.com).
The central bank’s notice said that these platforms are not authorised to deal in forex transactions under the Foreign Exchange Management Act (FEMA). RBI has repeatedly warned investors and consumers to avoid online platforms offering leveraged forex trading, margin trading, or contracts in foreign exchange not conducted through authorised channels.
RBI’s Alert List is intended to help the public identify entities that may pose risks, especially as online forex trading scams have been rising in recent years. The regulator has urged users to transact only through RBI-authorised dealers and refrain from using unregulated digital platforms that promise high returns. The central bank also reminds consumers that unauthorised forex trading can lead not only to financial losses but also to potential penalties under Indian law.
RBI’s ‘Alert List’ features platfoms that are not authorised to conduct foreign exchange transactions under the Foreign Exchange Management Act, 1999 (FEMA), nor permitted to run electronic trading platforms (ETPs) under the Electronic Trading Platforms (Reserve Bank) Directions, 2018.
‘Alert List’ also contains entities, platforms, and websites that appear to promote unauthorised forex platforms, whether through advertisements or by claiming to offer training or advisory services connected to such unauthorised entities.
The supply chain risk designation of the artificial intelligence firm is a first for a US company.
Source link
Thomas Fuller | SOPA Images | Lightrocket | Getty Images
UniQure needs to run another study to prove that its gene therapy “actually helps people with Huntington’s disease,” a senior U.S. Food and Drug Administration official said on a call with reporters Thursday.
The official, who requested anonymity before discussing sensitive information, confirmed the agency has asked the company to run a placebo controlled trial of its treatment, which is administered directly into the brain. UniQure has said that type of study isn’t ethical because it would require putting people under general anesthesia for hours, a characterization the official disputed.
“So what is really going on? UniQure is the latest company to make a failed therapy for Huntington’s patients,” the official said. “They likely acknowledge or understand at some deep level that their trial failed years ago, and instead of doing the right thing and running the correct clinical study, UniQure is performing a distorted or manipulated comparison in the mind of FDA.”
The comments mark the latest development in a messy public spat between UniQure and the FDA, and as the agency comes under fire for a number of recent drug approval application rejections, including some where companies have accused it of going back on previous guidance. FDA Commissioner Marty Makary in an interview with CNBC’s Becky Quick last week seemingly criticized UniQure’s gene therapy for Huntington’s disease. Makary didn’t name UniQure but described its treatment.
UniQure then accused the FDA of reversing its stance that the company’s clinical trial data would be sufficient to seek approval. UniQure’s study used an outside database to measure how patients with Huntington’s disease might decline without treatment, known as an external control. UniQure has said it wouldn’t be feasible to run a true randomized, double-blind placebo-controlled study, considered the gold standard, because it wouldn’t be ethical to make people undergo a sham hours-long brain surgery.
The FDA official said the agency “never agreed to accept this distorted comparison” and the FDA “never makes such assurances.” Instead, the “FDA will always say, ‘Well, we have to see the data when we get it.'”
UniQure didn’t immediately comment.
The company’s stock rose more than 10% on Thursday and has fallen 58% this year as of Thursday afternoon.
Business
US mortgage rates rise to 6% after three-week slide as oil-driven bond yields climb – The Times of India
The average long-term US mortgage rate edged higher this week, ending a three-week decline as bond yields rose amid oil-price pressures linked to the war with Iran.The benchmark 30-year fixed mortgage rate increased to 6% from 5.98% last week, mortgage buyer Freddie Mac said on Thursday. A year ago, the average rate stood at 6.63%, AP reported.The modest uptick breaks a three-week slide in borrowing costs, with mortgage rates having hovered close to the 6% mark for most of this year. Last week’s average had marked the first time the rate dipped below 6% since September 2022, reaching its lowest level in nearly three and a half years.Mortgage rates are influenced by several factors, including the Federal Reserve’s interest-rate policy, investor expectations about inflation and economic growth, and movements in the bond market.They typically track the direction of the 10-year US Treasury yield, which lenders use as a benchmark for pricing home loans.The 10-year Treasury yield rose to 4.14% at midday Thursday, up from around 4% a week earlier.Treasury yields have moved higher in recent days as rising oil prices added fresh inflation concerns, potentially complicating the Federal Reserve’s plans to cut interest rates.
Trump pays tribute to Lou Holtz after legendary football coach’s death
US Senate backs Trump’s Iran operations after House vote
Harry Kane calf injury imperils Bundesliga record chase
What are Iran’s ballistic missile capabilities?
India Us Trade Deal: Fresh look at India-US trade deal? May be ‘rebalanced’ if circumstances change, says Piyush Goyal – The Times of India
Attock Cement’s acquisition approved | The Express Tribune
-
Politics1 week agoWhat are Iran’s ballistic missile capabilities?
-
Business7 days ago
India Us Trade Deal: Fresh look at India-US trade deal? May be ‘rebalanced’ if circumstances change, says Piyush Goyal – The Times of India
-
Business1 week ago
Attock Cement’s acquisition approved | The Express Tribune
-
Politics1 week agoUS arrests ex-Air Force pilot for ‘training’ Chinese military
-
Fashion1 week agoPolicy easing drives Argentina’s garment import surge in 2025
-
Business6 days agoGreggs to reveal trading amid pressure from cost of living and weight loss drugs
-
Sports6 days agoLPGA legend shares her feelings about US women’s Olympic wins: ‘Gets me really emotional’
-
Fashion7 days agoTexwin Spinning showcasing premium cotton yarn range at VIATT 2026